Top Markets
#1 Akedo Akedo +59.54%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.99%
#4 Velvet Velvet +41.93%
#5 Black Phoenix Black Phoenix +34.52%
#6 τemplar τemplar +26.67%
#7 Ribbita by Virtuals Ribbita by Virtuals +18.08%
#8 Bitway Bitway +17.19%
#9 Cap Cap +17.11%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.52%
Coin of the day
Akedo Akedo
설정
언어
한국어
통화
USD
테마
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
주식 순위 #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
주가
$0.41
마지막 동기화: 2025-01-23
시가총액
$1.08M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 CohBar, Inc. (CWBR)

카테고리

Healthcare
CohBar, Inc. (CWBR)의 P/S 비율
August 2026 기준 P/S 비율 TTM: 0.00
CohBar, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0.00입니다. 2021년 말 기준 P/S 비율은 0.00였습니다.
CohBar, Inc.의 P/S 비율 기록 (2011 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
2026 (TTM) 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE